On May 6, 2025, Ocular Therapeutix (OCUL, Financial) was the subject of an updated analyst rating from Needham. Notably, analyst Serge Belanger maintained a "Buy" rating for OCUL, reflecting continued confidence in the stock's potential performance.
The price target for Ocular Therapeutix (OCUL, Financial) was adjusted from $15.00 to $14.00, marking a 6.67% decrease. This adjustment was made by Serge Belanger, who reaffirmed his recommendation despite the lowered target.
Ocular Therapeutix (OCUL, Financial) continues to trade on the NASDAQ exchange, and the latest analyst actions highlight the evolving perspectives in the investment community regarding its market performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for Ocular Therapeutix Inc (OCUL, Financial) is $17.45 with a high estimate of $22.00 and a low estimate of $14.00. The average target implies an upside of 125.80% from the current price of $7.73. More detailed estimate data can be found on the Ocular Therapeutix Inc (OCUL) Forecast page.
Based on the consensus recommendation from 12 brokerage firms, Ocular Therapeutix Inc's (OCUL, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Ocular Therapeutix Inc (OCUL, Financial) in one year is $3.68, suggesting a downside of 52.39% from the current price of $7.73. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Ocular Therapeutix Inc (OCUL) Summary page.
